⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL921570 | 0.83 | — | — | |
| SCHEMBL504031 | 0.72 | — | — | |
| SCHEMBL9386372 | 0.72 | — | — | |
| SCHEMBL6859254 | 0.72 | — | — | |
| SCHEMBL5532375 | 0.72 | — | — | |
| SCHEMBL16790286 | 0.72 | — | — | |
| SCHEMBL2758557 | 0.72 | — | — | |
| SCHEMBL770582 | 0.72 | — | — | |
| SCHEMBL9576685 | 0.62 | — | — | |
| SCHEMBL10525209 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3150 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009778-A1 | KRAS ANTAGONISTS | TRUETIVA INC (US) | 2025-01-09 | — | — | US | claimed |
| US-12116400-B2 | Albumin variants and conjugates | SARTORIUS ALBUMEDIX LIMITED (GB) | 2024-10-15 | — | — | US | claimed |
| EP-3243835-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-04-10 | — | — | EP | claimed |
| US-11952353-B2 | STAT3 transcription factor inhibitors and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2024-04-09 | — | — | US | claimed |
| EP-3337816-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-02-14 | — | — | EP | claimed |
| US-20230173295-A1 | Systems, Devices, and Methods for Gamma Entrainment using Sensory Stimuli to Alleviate Cognitive Deficits and/or Neuroinflammation Induced by Chemotherapy Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-08 | — | — | US | claimed |
| WO-2023055904-A1 | KRAS ANTAGONISTS | TRUETIVA, Inc. (US) | 2023-04-06 | — | — | WO | claimed |
| US-20230039076-A1 | ALBUMIN VARIANTS AND CONJUGATES | SARTORIUS ALBUMEDIX LIMITED (GB) | 2023-02-09 | — | — | US | claimed |
| US-20220117990-A1 | KRAS ANTAGONISTS | TRUETIVA, Inc. (US) | 2022-04-21 | — | — | US | claimed |
| US-20220017476-A1 | STAT3 TRANSCRIPTION FACTOR INHIBITORS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2022-01-20 | — | — | US | claimed |
| WO-2011076880-A1 | METHODS AND USE RELATED TO HUMANIN AND HUMANIN-LIKE PEPTIDES | ERIKSSON EMMA (SE) | 2011-06-30 | — | — | WO | claimed |
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE | 2009-08-27 | — | — | US | claimed |
| EP-0869933-B1 | IMPROVED FORMULATION FOR FERTILIZER ADDITIVE CONCENTRATE | IMC AGRICO CO (US) | 2009-06-24 | — | — | EP | claimed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | claimed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | claimed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | claimed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | claimed |
| US-20080138379-A1 | Preventing birth defects; administering formulation to women from preconception through first trimester of pregnancy | JENNINGS-SPRING BARBARA L | 2008-06-12 | — | — | US | claimed |
| EP-1015643-B1 | METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS | AGILENT TECHNOLOGIES INC (US) | 2005-09-21 | — | — | EP | claimed |
| US-6218118-B1 | MIXTURE OF NATURAL AND MASS-MODIFIED GENERIC OLIGONUCLEOTIDE PRECURSORS; USING MIXTURE AND ENZYMATIC PROCESSES TO ALTER THE LENGTH, AND THUS THE MASS, OF PRECURSORS THAT ARE COMPLEMENTARY TO TARGET NUCLEIC ACID | AGILENT TECHNOLOGIES, INC. | 2001-04-17 | — | — | US | claimed |